Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in relapsed mantle cell lymphoma
NCT01244009Phase 2Withdrawn
- Start
- Dec 2010
- Primary completion
- Aug 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of niraparib in mantle cell lymphoma (MCL). Primary endpoint: Objective Response Rate at 3 years. Planned start Dec 2010; status: withdrawn.
02
Drugs
niraparib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01244009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244009.